APG-1387 for Injection

DRUG4 trials

Sponsors

Ascentage Pharma Group Inc.

Conditions

Advanced Pancreatic CancerAdvanced Solid TumorAdvanced Solid Tumors or Hematologic MalignanciesChronic Hepatitis B

Phase 1

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

CompletedNCT03386526

Ascentage Pharma Group Inc.Advanced Solid Tumors or Hematologic Malignancies

Start: 2017-11-21End: 2022-11-30Updated: 2023-02-01

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

CompletedNCT03585322

Ascentage Pharma Group Inc.Chronic Hepatitis B

Start: 2018-07-04End: 2021-10-15Updated: 2021-11-08

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

TerminatedNCT04284488

Ascentage Pharma Group Inc.Advanced Solid Tumor

Start: 2020-04-10End: 2024-11-30Updated: 2026-01-08

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

TerminatedNCT04643405

Ascentage Pharma Group Inc.Advanced Pancreatic Cancer

Start: 2021-03-17End: 2024-12-10Updated: 2026-01-08

Related Papers

A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer

Cell Reports Medicine2025-09-23

Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells

Cancer Cell International2024-05-243 citations

Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.

Journal of Clinical Oncology2020-05-206 citations

A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-2011 citations

A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-209 citations